<DOC>
	<DOCNO>NCT01656239</DOCNO>
	<brief_summary>The purpose study determine dose level ( ) fedovapagon result decrease mean nocturnal void frequency .</brief_summary>
	<brief_title>Dose Range Finding Study Fedovapagon Men With Nocturia</brief_title>
	<detailed_description>Fedovapagon selective vasopressin V2 receptor ( V2 receptor ) agonist develop treatment Nocturia . The antidiuretic effect V2 receptor stimulation kidney well establish use peptide agonist , desmopressin , show clinical benefit diabetes insipidus , primary nocturnal enuresis Nocturia . Nocturia , define complaint individual wake night one time void , common complaint show age-dependent increase prevalence severity ( number Nocturnal Voids ) . It bothersome symptom benign prostatic hypertrophy ( BPH ) link age-dependent loss circadian release endogenous nocturnal vasopressin consequent production urine night ( Nocturnal Polyuria ) . The purpose Phase IIb study determine efficacy different dos fedovapagon reduce number time subject Nocturia void night together parameter include increase time go bed wake first void . By establish effective dos fedovapagon clinical endpoint , data study determine appropriate dose ( ) fedovapagon treatment Nocturia take forward study .</detailed_description>
	<mesh_term>Nocturia</mesh_term>
	<criteria>Males age 55 History and/ symptom Nocturia ( 2 5 void per night ) Generally well ( concomitant illness / condition well control ) Serum sodium , potassium , chloride bicarbonate within normal limit No clinically significant abnormality laboratory parameter , urinalysis , electrocardiogram ( ECG ) physical examination Prostate specific antigen ( PSA ) within normal range consider clinically significant Ability comply requirement study Written inform consent .</criteria>
	<gender>Male</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>VA106483 , fedovapagon , Nocturia , male , nocturnal void , anti-diuretic</keyword>
</DOC>